Saxagliptin

Summary

Saxagliptin is an oral prescription drug approved for the management of type 2 diabetes mellitus. It belongs to the dipeptidyl peptidase‑4 (DPP‑4) inhibitor class and is sold under brand names such as Onglyza and Kombiglyze XR. By enhancing the body’s own incretin response, saxagliptin helps lower blood glucose levels and is generally weight‑neutral.

Mechanism of Action

Saxagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally degrades the incretin hormones glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). Inhibition of DPP‑4 prolongs the activity of these hormones, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release from pancreatic α‑cells, thereby reducing post‑prandial glucose excursions.

What the Research Shows

Clinical trials have shown that saxagliptin effectively lowers glycated hemoglobin and fasting glucose in type 2 diabetes, with a neutral impact on body weight. A systematic review of fracture risk listed saxagliptin among DPP‑4 inhibitors that may increase fracture incidence, although the analysis did not provide a drug‑specific estimate. In heart‑failure populations, subanalyses indicate that DPP‑4 inhibitors do not reduce hospitalization risk, and saxagliptin specifically has been associated with a higher rate of heart‑failure hospitalization. Overall, evidence supports glycaemic benefit but highlights uncertainties regarding skeletal and cardiovascular safety.

Reported Benefits

Evidence from randomized trials demonstrates that saxagliptin reliably reduces blood glucose and HbA1c in adults with type 2 diabetes. Weight effects are neutral to modestly reducing, distinguishing it from some glucose‑lowering agents that cause weight gain. The oral route and once‑daily dosing support convenient use in routine diabetes care.

Limitations of the Evidence

Saxagliptin has not shown a reduction in heart‑failure hospitalization and may be linked to an increased risk of such events, limiting its suitability for patients with existing heart failure. The systematic fracture‑risk review suggests a potential increase in bone fractures, though data are indirect and drug‑specific estimates are lacking. Consequently, its cardiovascular and skeletal safety profiles remain less favorable compared with newer agents such as SGLT2 inhibitors.

Safety Considerations

Overall tolerability is favorable, with common adverse events including nasopharyngitis and mild gastrointestinal symptoms reported in trials. However, the association with higher heart‑failure hospitalization risk warrants caution in patients with established or high‑risk heart failure. The possible elevation in fracture risk, noted in a meta‑analysis of anti‑diabetic drugs, suggests monitoring bone health in susceptible individuals. As with all antidiabetic agents, hypoglycaemia is uncommon when saxagliptin is used as monotherapy but may occur when combined with insulin or sulfonylureas.

How It Is Administered

Saxagliptin is administered orally, typically as a tablet taken once daily with or without food. The extended‑release formulation (Kombiglyze XR) combines saxagliptin with metformin in a single tablet, but the active ingredient alone is also available as a standard tablet. No injection or infusion routes are required.

Routes of Administration

Goals & Uses

• Reduction of postprandial hyperglycemiaMetabolic / EndocrineHigh
• Weight neutralityBody CompositionModerate
• Low hypoglycemia riskSafety / TolerabilityHigh
• Glycemic control in type 2 diabetesMetabolicHigh
• Combination therapy with metforminMetabolic / EndocrineHigh

Contraindications

• Diabetic ketoacidosisMetabolicHigh
• Type 1 diabetes mellitusEndocrineHigh
• History of serious hypersensitivity to saxagliptinAllergic / ImmunologicHigh
• Heart failure (NYHA class III–IV)CardiovascularModerate

Adverse Effects

• PancreatitisGastrointestinalRareInflammation of the pancreas
• Heart failure hospitalizationCardiovascularUncommon
• Urinary tract infectionGenitourinaryCommon
• Upper respiratory tract infectionInfectiousCommon
• Hypoglycemia (when combined with insulin or sulfonylurea)MetabolicCommon
• AngioedemaImmunologicRare

Drug Interactions

• Insulin or insulin secretagogues (sulfonylureas)Moderate
• CYP3A4/5 inducers (e.g., rifampin, carbamazepine)Moderate
• Strong CYP3A4/5 inhibitors (e.g., ketoconazole, clarithromycin, atazanavir)Moderate
• ACE inhibitorsLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairment (severe)HepaticRelative
• Pediatric patients (<18 years)AgeAbsolute
• Heart failure (established)CardiovascularRelative
• Renal impairment (eGFR ≤50 mL/min/1.73m²)RenalRelative

Regulatory Status

• European UnionApprovedApproved: Type 2 diabetes mellitus in adults — as monotherapy or add-on combination therapyEMA approved October 1, 2009 (Onglyza). Also approved as Komboglyze (saxagliptin/metformin).
• United StatesApprovedApproved: Type 2 diabetes mellitus — adjunct to diet and exercise to improve glycemic control in adultsFDA approved July 31, 2009. Available as Onglyza (monotherapy) and Kombiglyze XR (with metformin XR). Label includes heart failure hospitalization warning.
• United KingdomApprovedApproved: Type 2 diabetes mellitus in adultsApproved via EMA prior to Brexit; continued approval maintained under MHRA post-Brexit.

FDA approved in 2009. EMA approved in 2009. Post-marketing cardiovascular outcomes trial (SAVOR-TIMI 53) showed a possible increased risk of heart failure hospitalization; label carries a warning for this risk.

Evidence & Sources

• Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis
  Journal ArticleHighZhang YS, et al.2021-01-01T00:00:00.000000Z
• Diabesity: therapeutic options
  Journal ArticleModerateColagiuri S2010-01-01T00:00:00.000000Z
• Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
  Journal ArticleModerateSeferović PM, et al.2018-01-01T00:00:00.000000Z

Frequently Asked Questions